midazolam and HbS Disease

midazolam has been researched along with HbS Disease in 5 studies

Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.

Research

Studies (5)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Effect of Low-dose Ketamine (LDK) on Opioid Usage in the ED

Opioid usage for at least one but up to three prior patient visits in the last one year for each patient enrolled in the study was summarized, expressed as morphine equivalents in mg/kg/h, to account for different types of opioids used per patient preference, and then this was compared to the intervention group that received LDK. Percent change in opioid usage (expressed as morphine equivalents in mg/kg/h) is reported). (NCT03296345)
Timeframe: Up to one year prior and after LDK administration on day 1 of the study in the ED

Effect of Low-dose Ketamine on Discharge Rates From the ED

"Percent discharge from the ED for intervention group and for at least one but up to three visits prior to receipt of ketamine in the last one year, were assessed. Participants were assigned a 0 if discharged or 1 if not discharged." (NCT03296345)
Timeframe: Up to one year prior to receipt of ketamine for the historical control arm/group and up to 18 months for the intervention arm/group

Effect of Low-dose Ketamine on Pain Scores on Presentation to the ED

Patient pain scores at presentation for the enrolled encounters and for at least one but up to three visits prior to receipt of ketamine in the last one year, were assessed. At least one but up to three prior visits were averaged and compared to the intervention visit. Pain was assessed using the faces pain scale which consists of a series of line diagrams of faces with expressions of increasing distress. The score ranges from 0 (no pain) to 10 (the worst pain). (NCT03296345)
Timeframe: Up to one year prior and on presentation to the ED after LDK administration

Effect of Low-dose Ketamine on Patient Pain Scores on Discharge From the ED/Admission to the Hospital

Patient pain scores at time of discharge from the ED/admission to the hospital for at least one but up to three visits prior to receipt of ketamine in the last one year, were assessed. At least one but up to three prior visits were averaged and compared to the intervention visit. Pain scores post receipt of ketamine are presented for the intervention group. Pain was assessed using the faces pain scale which consists of a series of line diagrams of faces with expressions of increasing distress. The score ranges from 0 (no pain) to 10 (the worst pain). (NCT03296345)
Timeframe: At time of discharge from the ED/admission to the hospital (up to one year prior and after LDK administration)

Effect of Low-dose Ketamine on Percent Difference of Length of Stay (LOS) in the ED

Length of stay (LOS) in minutes in the ED for at least one but up to three visits prior to receipt of ketamine in the last one year, were assessed. (NCT03296345)
Timeframe: Up to one year prior to and after LDK administration on day 1 of the study in the ED

Effect of Low-dose Ketamine on Time to 50% Pain Reduction

Time to 50% pain reduction (pain reported 50% less than baseline) in minutes for at least one but up to three visits prior to receipt of ketamine in the last one year, were assessed as historical controls. Pain was assessed using the faces pain scale which consists of a series of line diagrams of faces with expressions of increasing distress. The score ranges from 0 (no pain) to 10 (the worst pain). (NCT03296345)
Timeframe: Up to one year prior to and after LDK administration on day 1 of the study in the ED

Subjective Effect of Low Dose Ketamine on Pain Relief Assessed Via a Patient Survey

"After receipt of LDK, patients and/or their parents, based on age, filled out a survey based on a Likert scale regarding their agreement (Strongly Disagree to Strongly Agree) with the following statements: Achieved faster pain relief with LDK, Achieved more complete pain relief with LDK, and Desire to receive LDK in a future vaso-occlusive crisis. There is also an area where patients could provide general comments regarding their experience in receiving LDK.~Count of Participants who agree or strongly agree for each question are reported." (NCT03296345)
Timeframe: after LDK administration on day 1 of the study in the ED

Other Studies

5 other studies available for midazolam and HbS Disease